{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:23:31Z","timestamp":1790173411964,"version":"4.1.0"},"reference-count":51,"publisher":"American Chemical Society (ACS)","issue":"17","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Z01 BC 007333"],"award-info":[{"award-number":["Z01 BC 007333"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 007363"],"award-info":[{"award-number":["ZIA BC 007363"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Integrase mutations can reduce the effectiveness of the first-generation FDA-approved integrase strand transfer inhibitors (INSTIs), raltegravir (RAL) and elvitegravir (EVG). The second-generation agent, dolutegravir (DTG), has enjoyed considerable clinical success; however, resistance-causing mutations that diminish the efficacy of DTG have appeared. Our current findings support and extend the substrate envelope concept that broadly effective INSTIs can be designed by filling the envelope defined by the DNA substrates. Previously, we explored 1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides as an INSTI scaffold, making a limited set of derivatives, and concluded that broadly effective INSTIs can be developed using this scaffold. Herein, we report an extended investigation of 6-substituents as well the first examples of 7-substituted analogues of this scaffold. While 7-substituents are not well-tolerated, we have identified novel substituents at the 6-position that are highly effective, with the best compound (6p) retaining better efficacy against a broad panel of known INSTI resistant mutants than any analogues we have previously described.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.7b00596","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T12:27:21Z","timestamp":1500899241000},"page":"7315-7332","source":"Crossref","is-referenced-by-count":57,"title":["Structure-Guided\nOptimization of HIV Integrase Strand\nTransfer Inhibitors"],"prefix":"10.1021","volume":"60","author":[{"given":"Xue Zhi","family":"Zhao","sequence":"first","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , , ,","place":["Frederick, Maryland, United States, 21702"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Smith","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , , ,","place":["Frederick, Maryland, United States, 21702"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Maskell","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute , , ,","place":["London, United Kingdom, NW1 1AT"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Me\u0301tifiot","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , , ,","place":["Bethesda, Maryland, United States, 20892"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie E.","family":"Pye","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute , , ,","place":["London, United Kingdom, NW1 1AT"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Fesen","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , , ,","place":["Bethesda, Maryland, United States, 20892"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Marchand","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , , ,","place":["Bethesda, Maryland, United States, 20892"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pommier","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , , ,","place":["Bethesda, Maryland, United States, 20892"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cherepanov","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute , , ,","place":["London, United Kingdom, NW1 1AT"]},{"name":"Imperial College London , St-Mary\u2019s Campus, Norfolk Place , ,","place":["London, United Kingdom, W2 1PG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Hughes","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , , ,","place":["Bethesda, Maryland, United States, 20892"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9925-8586","authenticated-orcid":true,"suffix":"Jr.","given":"Terrence R.","family":"Burke","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , , ,","place":["Frederick, Maryland, United States, 21702"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"2026090314010496900_cit1","doi-asserted-by":"publisher","first-page":"12730","DOI":"10.1021\/acs.chemrev.6b00125","article-title":"Retroviral\nDNA integration","volume":"116","author":"Lesbats","year":"2016","journal-title":"Chem. Rev."},{"key":"2026090314010496900_cit2","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery\nof raltegravir, a potent, selective orally bioavailable HIV-integrase\ninhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"Summa","year":"2008","journal-title":"J. Med. Chem."},{"key":"2026090314010496900_cit3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1021\/jm0600139","article-title":"Novel HIV-1\nintegrase inhibitors derived from quinolone antibiotics","volume":"49","author":"Sato","year":"2006","journal-title":"J. Med. Chem."},{"key":"2026090314010496900_cit4","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1021\/jm400645w","article-title":"Carbamoyl\npyridone HIV-1 integrase Inhibitors 3. A diastereomeric approach to\nchiral nonracemic tricyclic ring systems and the discovery of dolutegravir\n(S\/GSKi349572) and (S\/GSK1265744)","volume":"56","author":"Johns","year":"2013","journal-title":"J. Med. Chem."},{"key":"2026090314010496900_cit5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors\nof strand\ntransfer that prevent integration and inhibit HIV-1 replication in\ncells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"2026090314010496900_cit6","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.1093\/nar\/gkw592","article-title":"Selectivity\nfor strand-transfer over 3\u2032-processing and susceptibility to\nclinical resistance of HIV-1 integrase inhibitors are driven by key\nenzyme\u2013DNA interactions in the active site","volume":"44","author":"Me\u0301tifiot","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2026090314010496900_cit7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1742-4690-6-103","article-title":"Comparative biochemical\nanalysis of HIV-1 subtype B and C integrase enzymes","volume":"6","author":"Bar-Magen","year":"2009","journal-title":"Retrovirology"},{"key":"2026090314010496900_cit8","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1038\/emboj.2012.118","article-title":"3\u2032-Processing\nand strand transfer\ncatalysed by retroviral integrase in crystallo","volume":"31","author":"Hare","year":"2012","journal-title":"EMBO J."},{"key":"2026090314010496900_cit9","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.1128\/JVI.00915-10","article-title":"Nature,\nposition, and frequency of mutations made in a single cycle of HIV-1\nreplication","volume":"84","author":"Abram","year":"2010","journal-title":"J. Virol."},{"key":"2026090314010496900_cit10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMra1004180","article-title":"Development of antiretroviral drug\nresistance","volume":"365","author":"Wainberg","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2026090314010496900_cit11","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1128\/AAC.06170-11","article-title":"Broad phenotypic\ncross-resistance\nto elvitegravir in HIV-infected patients failing on raltegravir-containing\nregimens","volume":"56","author":"Garrido","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090314010496900_cit12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns\nand\nimplications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr. Opin. Infect. Dis."},{"key":"2026090314010496900_cit13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/QCO.0b013e32835ba81c","article-title":"Evolution\nof HIV integrase resistance\nmutations","volume":"26","author":"Quashie","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"2026090314010496900_cit14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s40265-013-0121-4","article-title":"Dolutegravir: First\nglobal approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"2026090314010496900_cit15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV\nintegrase strand transfer inhibitors among clinical specimens in the\nunited states, 2009\u20132012","volume":"58","author":"Hurt","year":"2014","journal-title":"Clin. Infect.\nDis."},{"key":"2026090314010496900_cit16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40265-014-0256-y","article-title":"Dolutegravir:\nA review of its use in the management of HIV-1 infection in adolescents\nand adults","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"2026090314010496900_cit17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/COH.0b013e328356db89","article-title":"Resistance\nto HIV integrase inhibitors","volume":"7","author":"Mesplede","year":"2012","journal-title":"Curr. Opin. HIV\nAIDS"},{"key":"2026090314010496900_cit18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/sj.emboj.7601005","article-title":"Retroviral\nDNA integration: reaction pathway and critical intermediates","volume":"25","author":"Li","year":"2006","journal-title":"EMBO J."},{"key":"2026090314010496900_cit19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature08784","article-title":"Retroviral\nintasome assembly and inhibition of DNA strand transfer","volume":"464","author":"Hare","year":"2010","journal-title":"Nature"},{"key":"2026090314010496900_cit20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.aah5163","article-title":"Cryo-EM structures and atomic model\nof the HIV-1 strand transfer complex intasome","volume":"355","author":"Passos","year":"2017","journal-title":"Science"},{"key":"2026090314010496900_cit21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.aah7002","article-title":"A supramolecular assembly mediates\nlentiviral DNA integration","volume":"355","author":"Ballandras-Colas","year":"2017","journal-title":"Science"},{"key":"2026090314010496900_cit22","doi-asserted-by":"publisher","first-page":"11244","DOI":"10.1073\/pnas.200139397","article-title":"HIV-1 integrase\ninhibitors that compete with the target DNA substrate define a unique\nstrand transfer conformation for integrase","volume":"97","author":"Espeseth","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090314010496900_cit23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/mol.111.073189","article-title":"Structural\nand functional analyses of the second-generation integrase strand\ntransfer inhibitor dolutegravir (S\/GSK1349572)","volume":"80","author":"Hare","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"2026090314010496900_cit24","doi-asserted-by":"publisher","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition\nand the evolution of viral resistance","volume":"107","author":"Hare","year":"2010","journal-title":"Proc.\nNatl. Acad. Sci. U. S. A."},{"key":"2026090314010496900_cit25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrd3404","article-title":"Interfacial inhibitors: targeting macromolecular complexes","volume":"11","author":"Pommier","year":"2012","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090314010496900_cit26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1021\/jm401902n","article-title":"Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing\nHIV-1 integrase inhibitors having high antiviral potency against cells\nharboring raltegravir-resistant integrase mutants","volume":"57","author":"Zhao","year":"2014","journal-title":"J. Med. Chem."},{"key":"2026090314010496900_cit27","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1021\/jm5001908","article-title":"4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having\nhigh potency against raltegravir-resistant integrase mutants of HIV-1","volume":"57","author":"Zhao","year":"2014","journal-title":"J. Med. Chem."},{"key":"2026090314010496900_cit28","first-page":"132","article-title":"2017 Update of the\ndrug resistance mutations in HIV-1","volume":"14","author":"Wensing","year":"2017","journal-title":"Top. Anitivir.\nMed."},{"key":"2026090314010496900_cit29","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1021\/jm301550c","article-title":"Carbamoyl pyridone\nHIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result\nin superior antiviral and pharmacokinetic profiles","volume":"56","author":"Kawasuji","year":"2013","journal-title":"J. Med. Chem."},{"key":"2026090314010496900_cit30","doi-asserted-by":"publisher","first-page":"8154","DOI":"10.1021\/acs.jmedchem.5b01037","article-title":"Discovery of 2-pyridinone aminals:\nA prodrug strategy to advance a second generation of HIV-1 integrase\nstrand transfer inhibitors","volume":"58","author":"Raheem","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090314010496900_cit31","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1021\/acschembio.5b00948","article-title":"HIV-1 integrase\nstrand transfer inhibitors\nwith reduced susceptibility to drug resistant mutant integrases","volume":"11","author":"Zhao","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"2026090314010496900_cit32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1741-7015-11-249","article-title":"What if HIV were unable\nto develop\nresistance against a new therapeutic agent?","volume":"11","author":"Wainberg","year":"2013","journal-title":"BMC Med."},{"key":"2026090314010496900_cit33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/phar.1386","article-title":"Dolutegravir:\nA new integrase strand transfer inhibitor for the treatment of HIV","volume":"34","author":"Shah","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2026090314010496900_cit34","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1093\/jac\/dku095","article-title":"New raltegravir resistance pathways induce broad cross-resistance\nto all currently used integrase inhibitors","volume":"69","author":"Malet","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090314010496900_cit35","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.chembiol.2004.08.010","article-title":"Combating susceptibility\nto drug resistance: Lessons from HIV-1 protease","volume":"11","author":"King","year":"2004","journal-title":"Chem. Biol."},{"key":"2026090314010496900_cit36","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1021\/jm020270n","article-title":"Synthesis and structure\u2013affinity\nrelationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides\nwith potent serotonin 5-HT3 and dopamine D2 receptor antagonistic\nactivity","volume":"46","author":"Hirokawa","year":"2003","journal-title":"J. Med. Chem."},{"key":"2026090314010496900_cit37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1128\/AAC.39.2.320","article-title":"Inhibition of human\nimmunodeficiency virus integrase by bis-catechols","volume":"39","author":"LaFemina","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090314010496900_cit38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1468-1293.2008.00628.x","article-title":"Drug resistance profiles for the\nHIV integrase gene\nin patients failing raltegravir salvage therapy","volume":"9","author":"Charpentier","year":"2008","journal-title":"HIV Med."},{"key":"2026090314010496900_cit39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses\nof raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2026090314010496900_cit40","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1021\/cb400468c","article-title":"Testing the substrate-envelope\nhypothesis with designed pairs of compounds","volume":"8","author":"Shen","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"2026090314010496900_cit41","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures\nof HIV-1 reverse transcriptase\/TMC278 complexes: Strategic flexibility\nexplains potency against resistance mutations","volume":"105","author":"Das","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090314010496900_cit42","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1248\/cpb.48.1847","article-title":"An efficient\nsynthesis of 5-bromo-2-methoxy-6methylaminopyridine-3-carboxylic\nacid","volume":"48","author":"Hirokawa","year":"2000","journal-title":"Chem. Pharm. Bull."},{"key":"2026090314010496900_cit43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/cb300471n","article-title":"Activities, crystal\nstructures and molecular dynamics of dihydro-1H-isoindole derivatives,\ninhibitors of HIV-1 integrase","volume":"8","author":"Metifiot","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"2026090314010496900_cit44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1747-0285.2011.01270.x","article-title":"Bicyclic hydroxy-1H-pyrrolopyridine-trione\ncontaining\nHIV-1 integrase inhibitors","volume":"79","author":"Zhao","year":"2012","journal-title":"Chem. Biol. Drug\nDes."},{"key":"2026090314010496900_cit45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00438-004-1047-z","article-title":"A reverse\ngenetic approach for generating gene replacement mutants in Ustilago\nmaydis","volume":"272","author":"Brachmann","year":"2004","journal-title":"Mol. Genet. Genomics"},{"key":"2026090314010496900_cit46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"XDS","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr.,\nSect. D: Biol. Crystallogr."},{"key":"2026090314010496900_cit47","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is\nthe resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr., Sect. D:\nBiol. Crystallogr."},{"key":"2026090314010496900_cit48","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: Model-building tools for molecular\ngraphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr., Sect. D: Biol.\nCrystallogr."},{"key":"2026090314010496900_cit49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymeth.2011.07.005","article-title":"The Phenix software for automated\ndetermination of macromolecular structures","volume":"55","author":"Adams","year":"2011","journal-title":"Methods"},{"key":"2026090314010496900_cit50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular\ncrystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr., Sect. D:\nBiol. Crystallogr."},{"key":"2026090314010496900_cit51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/jm070715d","article-title":"2,3-Dihydro-6,7-dihydroxy-1H-isoindol-1-one-based\nHIV-1 integrase inhibitors","volume":"51","author":"Zhao","year":"2008","journal-title":"J. Med. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.7b00596","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/60\/17\/7315\/67315313\/acs.jmedchem.7b00596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/60\/17\/7315\/67315313\/acs.jmedchem.7b00596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:01:08Z","timestamp":1788458468000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/60\/17\/7315\/696877\/Structure-Guided-Optimization-of-HIV-Integrase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":51,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2017,7,24]]},"published-print":{"date-parts":[[2017,9,14]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00596","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]}}}